CM-PRP-HA provided significant pain relief and functional improvement.1
A prospective multicenter study was performed in patients with knee joint OA who did not respond to treatment with HA alone. Patients received 3 injections of the RegenPRP-HA combination prepared with Cellular Matrix® (CM-PRP-HA).
This study demonstrated that 3 injections of CM-PRP-HA is a new medical approach for patients who do not respond to treatment with HA alone and offers an alternative to knee surgery.1
83.6% success rate in patients who had an unsatisfactory clinical response to previous therapy with HA alone.1
Cellular Matrix technology: a safe, fast and novel treatment approach for OA of the knee.2
Fifty-three patients (90 knees), aged 39-80 years, suffering from knee osteoarthritis (Kellgren-Lawrence Grade I-III) were enrolled in a prospective randomized controlled clinical study comparing the clinical efficacy of Cellular Matrix (CM-PRP-HA) with two different types of HA: a non-crosslinked sodium hyaluronate (AV) and a non-crosslinked sodium hyaluronate combined with mannitol (OP).
The Cellular Matrix PRP-HA combination results in a longer and sustained clinical improvement than HA alone, and thus might be a useful tool for postponing arthroplasty.1,2